Skip to main content
SpringerLink
Log in

Reduced Chemotherapy Duration: A Good Idea?

  • Published:
Current Colorectal Cancer Reports

Abstract

Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given for 6 months, are the current standard of care. However, chronic peripheral neuropathy can result as a side effect of oxaliplatin use. Investigators have questioned whether the recommended duration of adjuvant therapy is necessary. This review discusses the history of adjuvant therapy for colon cancer and provides a rationale for an ongoing clinical trial collaboration addressing the optimal duration of adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. O'Connell MJ. Current status of adjuvant therapy for colorectal cancer. Oncology (Williston Park). 2004;18:751–5. discussion 755–8.

    Google Scholar 

  3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.

    Article  PubMed  CAS  Google Scholar 

  4. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–6.

    PubMed  CAS  Google Scholar 

  5. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11:1879–87.

    PubMed  CAS  Google Scholar 

  6. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8.

    Article  PubMed  Google Scholar 

  7. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345:939–44.

    Article  Google Scholar 

  8. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.

    Article  PubMed  CAS  Google Scholar 

  9. Haller D, Tabernero J, Maroun J, et al.: First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study) Presented at the Joint ECCO 15 - 34TH ESMO Multidisciplinary Congress, Berlin September 20–24, 2009.

  10. •• Kuebler JP, Wieand HS, O'Connell MJ, et al.: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198–2204. This study provides the rationale for the use of lower cumulative doses of oxaliplatin in the adjuvant setting.

    Article  PubMed  CAS  Google Scholar 

  11. •• Andre T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109–3116. A report of the updated results from the MOSAIC trial demonstrating an overall survival benefit with oxaliplatin in the adjuvant setting.

    Article  PubMed  CAS  Google Scholar 

  12. Saini A, Norman AR, Cunningham D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer. 2003;88:1859–65.

    Article  PubMed  CAS  Google Scholar 

  13. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005;16:549–57.

    Article  PubMed  CAS  Google Scholar 

  14. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053–71.

    Article  PubMed  CAS  Google Scholar 

  15. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5 Suppl 1:S38–46.

    Article  PubMed  CAS  Google Scholar 

  16. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25:2205–11.

    Article  PubMed  CAS  Google Scholar 

  17. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24:2368–75.

    Article  PubMed  CAS  Google Scholar 

  18. Link KH, Kornmann M, Staib L, et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg. 2005;242:178–87.

    Article  PubMed  Google Scholar 

  19. Kornmann M, Formentini A, Ette C, et al. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 2008;34:1316–21.

    PubMed  CAS  Google Scholar 

  20. Alberts SR, Sargent DJ, Smyrk TC, et al.: Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. [Abstract CRA3507]. Presented at the 2010 ASCO Annual Meeting Chicago, IL; June 4–8, 2010.

  21. Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery. Available at http://www.clinicaltrials.gov/ct2/show/NCT01150045. Assessed February 13, 2011.

  22. FOLFOX-4 3 months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer (TOSCA). Available at http://www.clinicaltrials.gov/ct2/show/NCT00646607. Assessed February 13, 2011.

  23. Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00749450. Assessed February 13, 2011.

  24. Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00958737. Assessed February 13, 2011.

  25. A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT01308086?term=NCT01308086. Assessed June 6, 2011.

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55901, USA

    Joleen Hubbard & Axel Grothey

Authors
  1. Joleen Hubbard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Grothey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joleen Hubbard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hubbard, J., Grothey, A. Reduced Chemotherapy Duration: A Good Idea?. Curr Colorectal Cancer Rep 7, 241–245 (2011). https://doi.org/10.1007/s11888-011-0100-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-011-0100-7

Keywords

Search

Navigation